文拉法辛与帕罗西汀治疗抑郁症临床疗效与安全性分析.docVIP

精品论文 参考文献 文拉法辛与帕罗西汀治疗抑郁症临床疗效与安全性分析 刘渝斌 　　（峨眉山市精神病医院精神科 四川 峨眉山 614213） 　　【摘要】 目的：探讨分析文拉法辛与帕罗西汀治疗抑郁症临床疗效与安全性。方法：选取我院近一年收治的52例抑郁症患者，随机分为文拉法辛组（26例）与帕罗西汀组（26例），疗程为8周，采用汉米尔抑郁量表（HAMD）来评定两组患者临床疗效，并采用症状量表（TESS）对治疗中出现的不良反应和安全性进行评定。结果：经过一个疗程治疗后，两组临床疗效没有显著性差异（Pgt;0.05）；但是文拉法辛组在治疗4周和6周时临床疗效优于帕罗西汀组（Plt;0.05）；并且文拉法辛组的不良反应发生率明显低于帕罗西汀组（Plt;0.05），差异具有统计学意义。结论：文拉法辛治疗抑郁症的临床疗效与帕罗西汀的临床疗效没显著差异，但是文拉法辛起效快，安全性高，值得推广应用。 　　【关键词】 抑郁症；文拉法辛；帕罗西汀；安全性 　　【中图分类号】R749 【文献标识码】A 【文章编号】2095-1752（2016）25-0014-02 　　Venlafaxine and paroxetine in the treatment of depression clinical efficacy and safety analysis 　　Liu Yubin. Emeishan Mental Hospital, Sichuan Province, Emeishan 614213, China 　　【Abstract】Objective Analysis of venlafaxine and paroxetine treating depression clinical efficacy and safety. Methods Choose our nearly a year of 52 patients with depression, were randomly divided into venlafaxine group (26 cases) and paroxetine group (26 cases) and treatment for 8 weeks, the han mill depression scale (HAMD) to evaluate the clinical efficacy of two groups of patients, and USES the symptom scale (TESS) for the treatment of the adverse reaction and safety of assess. Results After a course of treatment, there was no significant difference (Pgt; 0.05) clinical efficacy; however venlafaxine group at 4 weeks and 6 weeks clinical efficacy superior to paroxetine group (P lt;0.05); and venlafaxine Farthing incidence of adverse reactions was significantly lower than the paroxetine group (P lt;0.05), a statistically significant difference. Conclusion The clinical efficacy of venlafaxine in the treatment of depression no significant differences in clinical efficacy of paroxetine, venlafaxine but rapid onset, high security, should be widely applied. 　　【Key words】 Depression; Venlafaxine; Paroxetine;Security 　　抑郁症是临床精神科较为常见的一种疾病，也是世界上第四大致残的主要病因，会对患者的生活能力、生活质量造成严重影响，近年来抑郁症的发病率呈不断上升的趋势[1]。抑郁症属于高复发性疾病，临床主要采用巩固与维持抗抑郁药的治疗来降低其复发率[2]。为探讨文拉法辛与帕罗西汀治疗抑郁症临床疗效与安全性，本研究通过选取我院近一年收治的52例抑